

ABC-ANALYSIS OF RHEUMATOID ARTHRITIS PHARMACOTHERAPY

Gerasymova O.O., Tzhatirani Riyameke

National University of Pharmacy, Kharkov, Ukraine

Introduction. Rheumatoid arthritis is the serious autoimmune disease. It is caused by high rates disability and mortality of patients, reducing their quality of life and significant financial costs for treatment [2,3]. Conducting rational pharmacotherapy of the disease and optimization of its costs are relevant and determine the conduct of the clinical and economic evaluation of rheumatoid arthritis pharmacotherapy.

The purpose of this study is to evaluate the structure of medicinal preparations costs for the treatment of patients with rheumatoid arthritis in one of health care institutions in Kharkov.

Methods of research. Supplementary clinical and economic method: ABC-analysis [1]. Research lasted for 2015.

The main results. According to the 84 disease histories of patients with rheumatoid arthritis aged from 39 to 62 years (30 men and 54 women) 37 trade names (TN) of medicines (20 international non-patent names (INN)) from 13 pharmacological groups have been determined. Correlation of Ukrainian and foreign drugs is 1:2.7.

The division TN of medications into the ABC-groups was the following, group A – 9 medications with 79.46 % of costs from the total costs sum on all researched medications; group B – 11 medications (15.16 % of costs), group C – 17 medications (5.38 % of costs). The leader of ABC-rating according to TN became a immunosuppressant “Methotrexate” (“Ebewe Pharma”, tabl. 2.5 mg № 50) which is 22.92 % of total sum costs.

The most expensive pharmacological groups – immunosuppressants (38.74 % of costs, 2 INN, 2 TN) and nonsteroidal anti-inflammatory drugs (24.51% of costs, 2 INN, 6 TN).

Conclusion. The results of this carried out ABC-analysis can be the basis to improve the pharmacotherapy of rheumatoid arthritis in the mentioned health care institution.

References

1. Оцінка клінічної та економічної доцільності використання лікарських засобів у лікувально-профілактичному закладі (супровід формулярної системи): метод. рек. / А. М. Морозов, Л. В. Яковлева, Н. В. Бездітко та ін. – Х.: Стиль-Издат, 2013. – 36 с.
2. Florian MP Meier, Marc Frerix, Walter Hermann & Ulf Müller-Ladner. Current immunotherapy in rheumatoid arthritis // Immunotherapy. – 2013. – № 5(9). – P. 955-974.
3. Klimes J., Vocelka M., Sedova L. et al. Medical and Productivity Costs of Rheumatoid Arthritis in The Czech Republic: Cost-of-Illness Study Based on Disease Severity // Value in Health. Regional Issues – 2014. – № 4C. – P.75 – 81.